基于葡萄膜炎病史的COVID-19疫苗首剂接种后葡萄膜炎风险:匹配队列与交叉病例系列研究
该回顾性匹配队列与交叉病例系列研究纳入韩国2021年1月至2022年3月接种COVID-19疫苗且无COVID-19记录的7,917,457例随机样本,按葡萄膜炎病史分组并行3:1倾向评分匹配,评估接种后180天内非感染性葡萄膜炎的累积发病率和风险。匹配队列中葡萄膜炎组累积发病率15.4%显著高于对照组0.10%,但交叉病例系列分析显示接种前后180天内每20天间隔的葡萄膜炎发生频率相对均等,葡萄膜炎组调整后早期和晚期接种后事件的IRR分别为0.92(95%CI 0.88-0.96)和0.83(95%CI 0.80-0.85)。结论认为无论有无葡萄膜炎病史,COVID-19疫苗接种均未增加葡萄膜炎风险。
要点
- 匹配队列中葡萄膜炎组180天累积发病率为15.4%,显著高于对照组的0.10%。
- 交叉病例系列分析中,葡萄膜炎组接种后早期和晚期调整IRR分别为0.92和0.83。
- 结论认为无论有无葡萄膜炎病史,COVID-19疫苗接种均未增加葡萄膜炎风险。
核心结论
- 无论有无葡萄膜炎病史,COVID-19疫苗接种均未增加葡萄膜炎风险。
研究设计与样本
- 回顾性匹配队列与交叉病例系列研究,纳入韩国2021年1月至2022年3月接种COVID-19疫苗且无COVID-19记录的7,917,457例随机样本,按葡萄膜炎病史分为对照组和葡萄膜炎组,行3:1倾向评分匹配。
- 交叉病例系列分析比较有和无葡萄膜炎病史个体接种前后葡萄膜炎发病率比(IRR)。
主要发现
- 匹配队列分析中,葡萄膜炎组180天内葡萄膜炎累积发病率为15.4%,显著高于对照组的0.10%。
- 葡萄膜炎组在接种后前60天所有类型、前部和非前部葡萄膜炎的风险比(HR)分别为169、158和253,在61至180天分别为166、164和143。
- 交叉病例系列分析中,接种前后180天内每20天间隔的葡萄膜炎发生频率相对均等,与葡萄膜炎病史无关。
- 葡萄膜炎组接种后早期和晚期事件的调整IRR分别为0.92(95%CI 0.88-0.96)和0.83(95%CI 0.80-0.85)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the risk of noninfectious uveitis following the first dose of coronavirus disease 2019 (COVID-19) vaccination based on the uveitis history. DESIGN: Retrospective matched cohort and crossover case series study. METHODS: A random sample of 7 917 457 individuals who received COVID-19 vaccine between January 2021 and March 2022 in Korea, and had no recorded history of COVID-19 were categorized into the control and uveitis groups based on their uveitis history. After performing 3:1 propensity score matching, we assessed the cumulative incidence and risk of noninfectious uveitis in the 180 days after COVID-19 vaccination. Additionally, we performed a crossover case series analysis to compare the pre- and postvaccination incidence rate ratios (IRRs) of uveitis in individuals with and without a history of uveitis. RESULTS: In the matched cohort analysis, uveitis group had a significantly higher cumulative incidence of uveitis (15.4%) than control group (0.10%). The uveitis group exhibited increased risks of all uveitis types, anterior, and nonanterior uveitis in the first 60 days (hazard ratio [HR]: 169, 158, and 253, respectively) and in days 61 to 180 (HR: 166, 164, and 143, respectively) after vaccination. In the crossover case series analysis, uveitis occurred with relatively equal frequency in 20-day intervals during the 180 days before and after vaccination, regardless of uveitis history. For uveitis group, the adjusted IRRs for early and late postvaccination events were 0.92 (95% CI, 0.88-0.96) and 0.83 (95% CI, 0.80-0.85), respectively. CONCLUSIONS: COVID-19 vaccination did not increase the risk of uveitis, regardless of uveitis history.
引用
- Kim HR, Kim S, Chang MS, et al. Uveitis Risk After the First Dose of COVID-19 Vaccination Based on Uveitis History: Matched Cohort and Crossover Case Series Study. Am J Ophthalmol. 2024. PMID: 38341167. doi:10.1016/j.ajo.2024.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。